Palisade Bio (PALI) Income from Continuing Operations (2010 - 2026)
Palisade Bio's (PALI) quarterly Income from Continuing Operations came in at 10749000.0 in Q1 2026, down 365.12% year-on-year from 4054339.64 in Q1 2025, and down 7.64% on a QoQ basis from 9986000.0 in Q4 2025.
Palisade Bio (PALI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has 17 years of Income from Continuing Operations data on file, last reported at 10749000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 365.12% year-over-year to 10749000.0 in Q1 2026; TTM through Mar 2026 was 26507000.0, a 96.1% decrease from a year earlier, with the FY2025 full-year figure at 45342000.0, up 4.19% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 10749000.0, down from 9986000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PALI reached as high as 2311000.0 in Q1 2025 and fell as low as 38173000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 6374647.06 across 5 years, with a median of 3686000.0 in 2024.
- Across the five-year window, Income from Continuing Operations tumbled 871.08% in 2023 and soared 90.34% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 3851000.0 in 2022, then grew by 18.02% to 3157000.0 in 2023, then decreased by 7.29% to 3387000.0 in 2024, then plunged by 194.83% to 9986000.0 in 2025, then dropped by 7.64% to 10749000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 10749000.0 in Q1 2026, 9986000.0 in Q4 2025, and 2927000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Palisade Bio | 413.04 Mn | 280.41 Mn | - | -10.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.75 Mn |
| Dec 31, 2025 | -9.99 Mn |
| Sep 30, 2025 | -2.93 Mn |
| Jun 30, 2025 | -2.85 Mn |
| Mar 31, 2025 | -2.31 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | -3.60 Mn |
| Jun 30, 2024 | -4.22 Mn |
| Mar 31, 2024 | -3.69 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -3.80 Mn |
| Jun 30, 2023 | -3.61 Mn |
| Mar 31, 2023 | -38.17 Mn |
| Dec 31, 2022 | -3.85 Mn |
| Sep 30, 2022 | -4.50 Mn |
| Jun 30, 2022 | -3.64 Mn |
| Mar 31, 2022 | -3.93 Mn |
| Dec 31, 2021 | -6.36 Mn |
| Sep 30, 2021 | -3.04 Mn |
| Jun 30, 2021 | -33.51 Mn |